PROMIS questionnaires and smartphone mobility tracking after sarcoma surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with bone or soft-tissue sarcoma or giant cell tumor of bone who are scheduled for tumor resection will use a smartphone app to complete PROMIS questionnaires before surgery and at 6 weeks, 12 weeks, 6 months, and 12 months after surgery. The app will also passively collect mobility metrics such as daily step count, stairs climbed, and gait parameters. Researchers will compare PROMIS scores to the passive mobility data to validate PROMIS in this population and to characterize recovery trajectories following different surgical approaches. Enrollment is limited to English-speaking adults with an iPhone or Android device and excludes patients with metastatic bone tumors or certain tumor types, and the project is observational and conducted at centers in Calgary and at Mayo Clinic sites.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* Diagnosis of bone sarcoma, soft tissue sarcoma, or giant cell tumor of bone
* Tumors located in the pelvis, lower extremities, or upper extremities
* Primary or recurrent disease
* Undergoing operative tumor resection, including limb salvage surgery and amputation
* Has an iPhone or Android smartphone
* Speaks English

Exclusion Criteria:

* Metastatic bone tumor
* Diagnosis of atypical lipomatous tumor
* Diagnosis of dermatofibrosarcoma protuberans
* Currently pregnant or planning pregnancy within 6 months
* Unwilling or unable to attend follow-up evaluations
* Cognitive or communication barriers that impede completion of questionnaires

Where it's running

• Foothills Medical Centre, Arthur J Child Comprehensive Cancer Centre, University of Calgary
  Calgary, Alberta, Canada Recruiting
• Mount Sinai Hospital, University of Toronto
  Toronto, Ontario, Canada Recruiting
• Mayo Clinic
  Phoenix, Arizona, United States Not yet recruiting
• Mayo Clinic
  Rochester, Minnesota, United States Not yet recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MIGHTY: CAR T cells targeting B7-H3 for pediatric, teen, and young adult sarcoma

  This Phase 1 trial tests autologous hBRCA84D CAR T cells in kids, teens, and young adults (1–24) with relapsed or refractory RMS, ES, or DSRCT to see if the therapy is feasible and safe.

  Recruiting at 2 sites Phase 1 University College, London · London and 1 other locations · NCT07751380

• Lifileucel (Tumor-infiltrating lymphocytes) for advanced soft tissue sarcoma

  This study tests lifileucel, a cell therapy made from a patient’s own tumor cells, in adults with unresectable or metastatic soft tissue sarcoma who have had prior treatments to see if it helps shrink tumors and improve outcomes.

  Recruiting at 2 sites Phase 2 Iovance Biotherapeutics, Inc. · Tampa, Florida and 1 other locations · NCT07741877

• Domatinostat with Sirolimus for relapsed or refractory sarcoma and osteosarcoma

  This study tests whether the cancer drugs domatinostat and sirolimus together can help adolescents and adults whose sarcoma or osteosarcoma has come back or stopped responding to standard therapy.

  Recruiting at 2 sites Phase 1/2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida and 3 other locations · NCT07725380

• Clonal Hematopoiesis Effects with Chemo and Radiation in Solid Cancers

  This study tests whether clonal hematopoiesis affects outcomes for adults with solid cancers who are receiving chemotherapy or radiation.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07675967

• AYA Sarcoma Survivors: Personalized Exercise Program Pilot

  This pilot tests a personalized 12-week exercise program for adolescents and young adults with sarcoma to see if a triage tool can connect them with the right rehabilitation and exercise services.

  Recruiting at 3 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT07662239

• Fluorescence-guided surgery to reduce unexpected positive margins in high-grade sarcoma

  This phase II trial tests whether adding fluorescence-guided surgery with indocyanine green can lower unexpected positive margins in patients with high-grade sarcoma compared to standard surgery.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT07650656

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.